{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:32:55Z","timestamp":1789662775088,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministry of Higher Education \u2013 Libya","award":["8152"],"award-info":[{"award-number":["8152"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.yexcr.2017.09.012","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T10:46:21Z","timestamp":1504867581000},"page":"226-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture"],"prefix":"10.1016","volume":"360","author":[{"given":"A.","family":"Arhoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Chantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Haywood-Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2017.09.012_bib1","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1007\/s13277-014-1659-9","article-title":"Gene set enrichment analysis of the NF-\u03baB\/Snail\/YY1\/RKIP circuitry in multiple myeloma","volume":"35","author":"Zaravinos","year":"2014","journal-title":"Tumor Biol."},{"issue":"Supplement 7","key":"10.1016\/j.yexcr.2017.09.012_bib2","doi-asserted-by":"crossref","first-page":"vii313","DOI":"10.1093\/annonc\/mdq363","article-title":"Multiple myeloma","volume":"21","author":"Blad\u00e9","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.leukres.2013.05.014","article-title":"Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features","volume":"37","author":"Lemancewicz","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.yexcr.2017.09.012_bib4","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2017.09.012_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2017.09.012_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/bbrc.1999.1641","article-title":"TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells","volume":"265","author":"Yamada","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2017.09.012_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00280-010-1544-1","article-title":"Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors","volume":"68","author":"Doi","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib8","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non\u2013small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.yexcr.2017.09.012_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23822","article-title":"A multicenter, open\u2010label phase II study of recombinant CPT (circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma","volume":"89","author":"Geng","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3892\/br.2016.650","article-title":"Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines","volume":"4","author":"Jian","year":"2016","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.yexcr.2017.09.012_bib12","doi-asserted-by":"crossref","first-page":"e75414","DOI":"10.1371\/journal.pone.0075414","article-title":"Sorafenib sensitizes solid tumors to Apo2L\/TRAIL and Apo2L\/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis","volume":"8","author":"Abdulghani","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.yexcr.2017.09.012_bib13","article-title":"Histone deacetylase inhibitors in multiple myeloma","volume":"1","author":"Deleu","year":"2009","journal-title":"Hematol. Rev."},{"key":"10.1016\/j.yexcr.2017.09.012_bib14","doi-asserted-by":"crossref","first-page":"R546","DOI":"10.1016\/j.cub.2004.07.007","article-title":"Histones and histone modifications","volume":"14","author":"Peterson","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12185-013-1290-3","article-title":"Histone deacetylase inhibitors in the treatment for multiple myeloma","volume":"97","author":"Hideshima","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2017.09.012_bib18","doi-asserted-by":"crossref","unstructured":"Sayers Thomas, Cross Neil, Triggering death receptors to promote cancer cell death, in: Anonymous , 2014.","DOI":"10.1093\/med\/9780199676866.003.0008"},{"key":"10.1016\/j.yexcr.2017.09.012_bib19","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/jid.2012.125","article-title":"Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling","volume":"132","author":"Al-Yacoub","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.yexcr.2017.09.012_bib20","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1038\/cddis.2013.306","article-title":"Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL\/MD5-1 or 5-azacytidine using syngeneic Vk* MYC multiple myeloma","volume":"4","author":"Matthews","year":"2013","journal-title":"Cell death Dis."},{"key":"10.1016\/j.yexcr.2017.09.012_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1593\/neo.04655","article-title":"Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma","volume":"7","author":"Fandy","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.yexcr.2017.09.012_bib22","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2008-06-164178","article-title":"Myeloma research goes 3D","volume":"112","author":"Jelinek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2017.09.012_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1732","article-title":"The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration","volume":"7","author":"Le Maitre","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.yexcr.2017.09.012_bib24","doi-asserted-by":"crossref","first-page":"e35830","DOI":"10.1371\/journal.pone.0035830","article-title":"Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo","volume":"7","author":"Vitovski","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.yexcr.2017.09.012_bib25","doi-asserted-by":"crossref","first-page":"e31594","DOI":"10.1371\/journal.pone.0031594","article-title":"Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL","volume":"7","author":"Kagawa","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.yexcr.2017.09.012_bib26","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells","volume":"2","author":"Rosato","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yexcr.2017.09.012_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.cdd.4402260","article-title":"Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways","volume":"15","author":"McStay","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2017.09.012_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nmeth1085","article-title":"Engineering tumors with 3D scaffolds","volume":"4","author":"Fischbach","year":"2007","journal-title":"Nat. Methods"},{"key":"10.1016\/j.yexcr.2017.09.012_bib29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.4161\/cc.25163","article-title":"Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition","volume":"12","author":"Amatangelo","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.yexcr.2017.09.012_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2014.02.016","article-title":"Enrichment of cancer stem cell-like cells by culture in alginate gel beads","volume":"177","author":"Xu","year":"2014","journal-title":"J. Biotechnol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717304883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717304883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:14:55Z","timestamp":1762146895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482717304883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0014482717304883"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.012","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}